Call for Adoption of Synchronized Biweekly Dosing of Anti-EGFR Agent Cetuximab: Implications for Patients with Metastatic Colorectal Cancer, and Squamous Cell Carcinoma of the Head and Neck

被引：2
|
作者：
Kasi, Pashtoon Murtaza [1 ]
机构：
[1] Weill Cornell Med, Meyer Canc Ctr, Englander Inst Precis Med, 1305 York Ave, New York, NY 10021 USA
来源：
ONCOLOGIST | 2022年 / 27卷 / 05期
关键词：
D O I：
10.1093/oncolo/oyac070
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：336 / 337
页数：2
相关论文
共 50 条
  • [41] Cetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN): An interim analysis
    Kies, M. S.
    Gibson, M. K.
    Kim, S. W.
    Savvides, P.
    Blumenschein, G. R., Jr.
    Worden, F.
    Chen, H.
    Grandis, J. R.
    Argiris, A. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [42] Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC)
    Hitt, R.
    Irigoyen, A.
    Nunez, J.
    Grau, J.
    Garcia Saenz, J.
    Pastor, M.
    Jara, C.
    Garcia Giron, C.
    Hidalgo, M.
    Cruz Hernandez, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] Novel anti-EGFR scFv human antibody-conjugated immunoliposomes enhance chemotherapeutic efficacy in squamous cell carcinoma of head and neck
    Wang, Yi-Ping
    Liu, I-Ju
    Chung, Meng-Jhe
    Wu, Han-Chung
    ORAL ONCOLOGY, 2020, 106
  • [44] A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma
    Kochanny, Sara E.
    Worden, Francis P.
    Adkins, Douglas R.
    Lim, Dean W.
    Bauman, Julie E.
    Wagner, Stephanie A.
    Brisson, Ryan J.
    Karrison, Theodore G.
    Stadler, Walter M.
    Vokes, Everett E.
    Seiwert, Tanguy Y.
    CANCER, 2020, 126 (10) : 2146 - 2152
  • [45] Concurrent chemoradiation (CCRT) or radiotherapy with anti-EGFR directed monoclonal antibody (anti-EGFR) or CCRT plus anti-EGFR in locoregionally advanced head-and-neck squamous cell carcinoma (LA-HNSCC): a comprehensive review of randomized data
    Specenier, P.
    Janssens, K.
    Vermorken, J. B.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S105 - S106
  • [46] The anti-EGFR antibody cetuximab sensitizes human head and neck squamous cell carcinoma cells to radiation in part through inhibiting radiation-induced upregulation of HIF-1α
    Lu, Haiquan
    Liang, Ke
    Lu, Yang
    Fan, Zhen
    CANCER LETTERS, 2012, 322 (01) : 78 - 85
  • [47] Preclinical evaluation of IMGN289, an anti-EGFR antibody-maytansinoid conjugate for the treatment of squamous cell carcinoma of the head and neck
    Ponte, Jose F.
    Setiady, Yulius Y.
    Dong, Ling
    Skaletskaya, Anna
    Carrigan, Christina N.
    Anderson-Villaluz, Alfred
    Lutz, Robert J.
    Pinkas, Jan
    CANCER RESEARCH, 2013, 73 (08)
  • [48] Concurrent chemoradiation (CCRT) or radiotherapy (RT) with anti-EGFR directed monocolonal antibody (antiEGFR) or CCRT plus anti-EGFR in locoregionally advanced squamous cell carcinoma of the head and neck LA-HNSCC)
    Janssens, Katleen
    Vermorken, Jan B.
    Specenier, Pol
    ACTA CLINICA BELGICA, 2016, 71 : 18 - 18
  • [49] Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy
    Siano, Marco
    Infante, Gabriele
    Resteghini, Carlo
    Cau, Maria Chiara
    Alfieri, Salvatore
    Bergamini, Cristiana
    Granata, Roberta
    Miceli, Rosalba
    Locati, Laura
    Licitra, Lisa
    Bossi, Paolo
    ORAL ONCOLOGY, 2017, 69 : 33 - 37
  • [50] Paclitaxel in combination with anti-EGFR therapy as induction chemotherapy for patients unfit for cisplatin with locally advanced head and neck squamous cell carcinoma (LA-HNSCC)
    Marin, J. A.
    Oliva Bernal, M.
    Plana Serrahima, M.
    Ferrer, M.
    Vilarino Quintela, N.
    Vazquez, S.
    Vilajosana, E.
    Lozano, A.
    Nogues, J.
    Mari, A.
    Bermejo, O.
    Mesia Nin, R.
    Taberna Sanz, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 383 - 383
12345